Full Text Journal Articles by
Author Jose A Karam

Advertisement

Find full text journal articles






Sarcomatoid features and lymph node-positive disease in chromophobe renal cell carcinoma.

Alberto C Pieretti, Mary E Westerman, Alexandria Childs, Niki Millward, Daniel D Shapiro, Kanishka Sircar, Priya Rao, Eric Jonasch, Matthew T Campbell, Nizar M Tannir, Surena F Matin, Christopher G Wood, Jose A Karam,

<h4>Purpose</h4>The presence of sarcomatoid features and/or lymph node-positive disease may be associated with a worse prognosis in chromophobe renal cell carcinoma (ChRCC). We sought to better characterize patients' long-term outcomes with these features compared with those without these features.<h4>Materials and methods</h4>We identified 300 patients treated for sporadic, unilateral, nonmetastatic ChRCC ... Read more >>

Urol Oncol (Urologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-up: AUA Guideline: Part II.

Steven C Campbell, Robert G Uzzo, Jose A Karam, Sam S Chang, Peter E Clark, Lesley Souter,

<h4>Purpose</h4>This AUA Guideline focuses on active surveillance (AS) and follow-up after intervention for adult patients with clinically-localized renal masses suspicious for cancer, including solid enhancing tumors and Bosniak 3/4 complex cystic lesions.<h4>Materials and methods</h4>In January 2021, the Renal Mass and Localized Renal Cancer guideline underwent additional amendment based on a ... Read more >>

J Urol (The Journal of urology)
[2021, 206(2):209-218]

Cited: 0 times

View full text PDF listing >>



Advertisement

Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I.

Steven C Campbell, Peter E Clark, Sam S Chang, Jose A Karam, Lesley Souter, Robert G Uzzo,

<h4>Purpose</h4>This AUA Guideline focuses on evaluation/counseling/management of adult patients with clinically-localized renal masses suspicious for cancer, including solid-enhancing tumors and Bosniak 3/4 complex-cystic lesions.<h4>Materials/methods</h4>The Renal Mass and Localized Renal Cancer guideline underwent an update literature review which resulted in the 2021 amendment. When sufficient evidence existed, the body of evidence ... Read more >>

J Urol (The Journal of urology)
[2021, 206(2):199-208]

Cited: 0 times

View full text PDF listing >>



Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation.

Brian De, Aradhana M Venkatesan, Pavlos Msaouel, Amol J Ghia, Jing Li, Debra N Yeboa, Quynh-Nhu Nguyen, Andrew J Bishop, Eric Jonasch, Amishi Y Shah, Matthew T Campbell, Jennifer Wang, Amado J Zurita-Saavedra, Jose A Karam, Christopher G Wood, Surena F Matin, Nizar M Tannir, Chad Tang,

<h4>Objective</h4>To study whether delivering definitive radiotherapy (RT) to sites of oligoprogression in metastatic renal cell carcinoma (mRCC) enabled deferral of systemic therapy (ST) changes without compromising disease control or survival.<h4>Patients and methods</h4>We identified patients with mRCC who received RT to three or fewer sites of extracranial progressive disease between 2014 ... Read more >>

BJU Int (BJU international)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Correction: Macrophage HIF-1α Is an Independent Prognostic Indicator in Kidney Cancer.

Sophie J Cowman, Daniel G Fuja, Xian-De Liu, Rebecca S Slack Tidwell, Neelima Kandula, Deepika Sirohi, Archana M Agarwal, Lyska L Emerson, Sheryl R Tripp, Jeffrey S Mohlman, Miekan Stonhill, Guillermina Garcia, Christopher J Conley, Adam A Olalde, Timothy Sargis, Adela Ramirez-Torres, Jose A Karam, Christopher G Wood, Kanishka Sircar, Pheroze Tamboli, Kenneth Boucher, Benjamin Maughan, Benjamin T Spike, Thai H Ho, Neeraj Agarwal, Eric Jonasch, Mei Yee Koh,

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2021, 27(11):3265]

Cited: 0 times

View full text PDF listing >>



Role of lymph node dissection at the time of open or minimally invasive nephroureterectomy.

Andrew G McIntosh, Eric C Umbreit, Christopher G Wood, Surena F Matin, Jose A Karam,

Unlike urothelial carcinoma of the bladder, there is no guideline-based consensus on whether a lymph node dissection (LND) should be performed at the time of radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC). Variable lymphatic drainage based on primary tumor location, lack of prospective trials, and difficulties in developing ... Read more >>

Transl Androl Urol (Translational andrology and urology)
[2021, 10(5):2233-2245]

Cited: 0 times

View full text PDF listing >>



Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma.

Andrew J Wiele, Devaki Shilpa Surasi, Priya Rao, Kanishka Sircar, Xiaoping Su, Tharakeswara K Bathala, Amishi Y Shah, Eric Jonasch, Vince D Cataldo, Giannicola Genovese, Jose A Karam, Christopher G Wood, Nizar M Tannir, Pavlos Msaouel,

<h4>Purpose</h4>To assess the efficacy and safety of bevacizumab plus erlotinib in patients with RMC.<h4>Methods</h4>We retrospectively reviewed the records of patients with RMC treated with bevacizumab plus erlotinib at our institution.<h4>Results</h4>Ten patients were included in the study. Two patients achieved a partial response (20%) and seven patients achieved stable disease (70%). ... Read more >>

Cancers (Basel) (Cancers)
[2021, 13(9):]

Cited: 0 times

View full text PDF listing >>



Outcomes of Percutaneous Thermal Ablation for Biopsy-Proven T1a Renal Cell Carcinoma in Patients With Other Primary Malignancies.

Mohamed E Abdelsalam, Sharjeel H Sabir, Samuel B Kusin Ba, Jose A Karam, Surena F Matin, Christopher G Wood, Kamran Ahrar,

<b>OBJECTIVE.</b> The purpose of this article is to investigate the oncologic effectiveness and survival outcomes of percutaneous image-guided thermal ablation for clinical T1a renal cell carcinoma (RCC) in patients with other primary nonrenal malignancies. <b>MATERIALS AND METHODS.</b> We reviewed records of patients with histologically proven T1a RCC (< 4.0 cm) ... Read more >>

AJR Am J Roentgenol (AJR. American journal of roentgenology)
[2021, 217(1):157-163]

Cited: 0 times

View full text PDF listing >>



The current role of cytoreductive nephrectomy for metastatic renal cell carcinoma.

Eric C Umbreit, Andrew G McIntosh, Chalairat Suk-Ouichai, Jose A Karam, Christopher G Wood,

The management of metastatic renal cell carcinoma (mRCC) continues to be a therapeutic challenge; however, the options for systemic therapy in this setting have exploded over the past 20 years. From the advent of toxic cytokine therapy to the subsequent discovery of targeted therapy (TT) and immune checkpoint inhibitors, the ... Read more >>

Indian J Urol (Indian journal of urology : IJU : journal of the Urological Society of India)
[2021, 37(1):13-19]

Cited: 0 times

View full text PDF listing >>



Origin of Subsequent Malignant Neoplasms in Patients with History of Testicular Germ Cell Tumor.

Eric C Umbreit, Bilal A Siddiqui, Michael J Hwang, Aron Y Joon, Tapati Maity, Mary E Westerman, Kelly W Merriman, Hussam Alhasson, Joma Uthup, Tao Guo, Joseph A Moore, John F Ward, Jose A Karam, Christopher G Wood, Louis L Pisters, Miao Zhang, Shi-Ming Tu,

Although genetic changes may be pivotal in the origin of cancer, cellular context is paramount. This is particularly relevant in a progenitor germ cell tumor and its differentiated mature teratoma counterpart when it concerns tumor heterogeneity and cancer dormancy in subsequent second malignancies (subsequent malignant neoplasms (SMNs)). From our tumor ... Read more >>

Cancers (Basel) (Cancers)
[2020, 12(12):]

Cited: 1 time

View full text PDF listing >>



Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma.

Christopher G Wood, James E Ferguson, Joel S Parker, Dominic T Moore, Jennifer G Whisenant, Susan J Maygarden, Eric M Wallen, William Y Kim, Mathew I Milowsky, Kathryn E Beckermann, Nancy B Davis, Scott M Haake, Jose A Karam, Dante S Bortone, Benjamin G Vincent, Thomas Powles, W Kimryn Rathmell,

BACKGROUNDSurgery remains the frontline therapy for patients with localized clear cell renal cell carcinoma (ccRCC); however, 20%-40% recur. Angiogenesis inhibitors have improved survival in metastatic patients and may result in responses in the neoadjuvant setting. The impact of these agents on the tumor genetic heterogeneity or the immune milieu is ... Read more >>

JCI Insight (JCI insight)
[2020, 5(22):]

Cited: 2 times

View full text PDF listing >>



Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors.

Jad Chahoud, Pavlos Msaouel, Jeremy A Ross, Barrett Z McCormick, Tharakeswara K Bathala, Jianjun Gao, Robert Horn, Lianchun Xiao, Kanishka Sircar, Matthew T Campbell, Amishi Y Shah, Sangeeta Goswami, Amado J Zurita, Eric Jonasch, Surena F Matin, Christopher G Wood, Jose A Karam, Padmanee Sharma, Nizar M Tannir,

<h4>Introduction</h4>Metastatic renal cell carcinoma with sarcomatoid dedifferentiation (sRCC) is associated with poor survival outcomes. We aimed to analyze the efficacy and safety of immune checkpoint inhibitors (ICI) in patients with sRCC comparing clear-cell (sccRCC) to non-clear cell epithelial histology (snccRCC).<h4>Methods</h4>We performed retrospective analysis of sRCC patients who received ICI at ... Read more >>

Urol Oncol (Urologic oncology)
[2021, 39(2):134.e9-134.e16]

Cited: 0 times

View full text PDF listing >>



Sarcomatoid renal cell carcinoma: biology, natural history and management.

Kyle A Blum, Sounak Gupta, Satish K Tickoo, Timothy A Chan, Paul Russo, Robert J Motzer, Jose A Karam, A Ari Hakimi,

Sarcomatoid dedifferentiation is an uncommon feature that can occur in most histological subtypes of renal cell carcinomas (RCCs) and carries a decidedly poor prognosis. Historically, conventional treatments for sarcomatoid RCCs (sRCCs) have shown little efficacy, and median survival is commonly 6-13 months. Despite being first described in 1968, the mechanisms ... Read more >>

Nat Rev Urol (Nature reviews. Urology)
[2020, 17(12):659-678]

Cited: 1 time

View full text PDF listing >>



Intraoperative and early postoperative complications in postchemotherapy retroperitoneal lymphadenectomy among patients with germ cell tumors using validated grading classifications.

Eric C Umbreit, Andrew G McIntosh, Chalairat Suk-Ouichai, Luis A Segarra, Levi C Holland, Bryan M Fellman, Stephen B Williams, Arun Z Thomas, Shi-Ming Tu, Curtis A Pettaway, Louis L Pisters, John F Ward, Christopher G Wood, Jose A Karam,

<h4>Background</h4>Postchemotherapy retroperitoneal lymphadenectomy (PC-RPLND) is an essential, yet potentially morbid, therapy for the management of patients with advanced germ cell tumors. In the current study, the authors sought to define the complication profile of PC-RPLND using validated grading systems for intraoperative adverse events (iAEs) and early postoperative complications.<h4>Methods</h4>Between 2000 and ... Read more >>

Cancer (Cancer)
[2020, 126(22):4878-4885]

Cited: 1 time

View full text PDF listing >>



Cytoreductive Nephrectomy in Patients Presenting With Advanced Disease: Have We Finally Answered the Question?

Daniel D Shapiro, Mary E Westerman, Jose A Karam, Christopher G Wood,

Determining the appropriate patients for cytoreductive nephrectomy (CN) has evolved with the integration of more effective systemic therapies for patients with metastatic renal cell carcinoma (mRCC). While previously considered to be first-line therapy for mRCC, CN has not demonstrated a significant survival advantage over systemic therapy in more recent randomized ... Read more >>

Cancer J (Cancer journal (Sudbury, Mass.))
[2020, 26(5):382-389]

Cited: 0 times

View full text PDF listing >>



Survival following cytoreductive nephrectomy: a comparison of existing prognostic models.

Mary E Westerman, Daniel D Shapiro, Nizar M Tannir, Matthew T Campbell, Surena F Matin, Jose A Karam, Christopher G Wood,

<h4>Objective</h4>To validate models currently used to predict metastatic renal cell carcinoma (mRCC) outcomes in a cohort of patients undergoing cytoreductive nephrectomy (CN).<h4>Patients and methods</h4>A total of 10 RCC prognostic models (International Metastatic RCC Database Consortium [IMDC]; Memorial Sloan Kettering Cancer Center [MSKCC]; Culp; Leibovich; University of California at Los Angeles ... Read more >>

BJU Int (BJU international)
[2020, 126(6):745-753]

Cited: 1 time

View full text PDF listing >>



Macrophage HIF-1α Is an Independent Prognostic Indicator in Kidney Cancer.

Sophie J Cowman, Daniel G Fuja, Xian-De Liu, Rebecca S Slack Tidwell, Neelima Kandula, Deepika Sirohi, Archana M Agarwal, Lyska L Emerson, Sheryl R Tripp, Jeffrey S Mohlman, Miekan Stonhill, Guillermina Garcia, Christopher J Conley, Adam A Olalde, Timothy Sargis, Adela Ramirez-Torres, Jose A Karam, Christopher G Wood, Kanishka Sircar, Pheroze Tamboli, Kenneth Boucher, Benjamin Maughan, Benjamin T Spike, Thai H Ho, Neeraj Agarwal, Eric Jonasch, Mei Yee Koh,

<h4>Purpose</h4>Clear cell renal cell carcinoma (ccRCC) is frequently associated with inactivation of the von Hippel-Lindau tumor suppressor, resulting in activation of HIF-1α and HIF-2α. The current paradigm, established using mechanistic cell-based studies, supports a tumor promoting role for HIF-2α, and a tumor suppressor role for HIF-1α. However, few studies have ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2020, 26(18):4970-4982]

Cited: 2 times

View full text PDF listing >>



Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy.

Andrew G McIntosh, Eric C Umbreit, Levi C Holland, Cindy Gu, Nizar M Tannir, Surena F Matin, Jose A Karam, Stephen H Culp, Christopher G Wood,

<h4>Background</h4>The management of metastatic renal cell carcinoma (mRCC) has evolved rapidly, and results from the Cancer du Rein Metastatique Nephrectomie et Antiangiogéniques (CARMENA) trial bring into question the utility of cytoreductive nephrectomy (CN). The objective of this study was to examine overall survival (OS) and identify risk factors associated with ... Read more >>

Cancer (Cancer)
[2020, 126(17):3950-3960]

Cited: 2 times

View full text PDF listing >>



Neoadjuvant Therapy for Locally Advanced Renal Cell Carcinoma.

Mary E Westerman, Daniel D Shapiro, Christopher G Wood, Jose A Karam,

There has been strong interest in using neoadjuvant therapy to decrease recurrence rates and facilitate surgical resection in locally advanced renal cell carcinoma. To date, no evidence exists to support improvement in oncologic outcomes with neoadjuvant therapy. Likewise, although targeted therapies have shown efficacy in tumor downsizing, this does not ... Read more >>

Urol Clin North Am (The Urologic clinics of North America)
[2020, 47(3):329-343]

Cited: 0 times

View full text PDF listing >>



EDITORIAL COMMENT.

Daniel D Shapiro, Jose A Karam, Christopher G Wood,

Urology (Urology)
[2020, 136:175]

Cited: 0 times

View full text PDF listing >>



Stereotactic Body Radiation Therapy for the Definitive Treatment of Early Stage Kidney Cancer: A Survival Comparison With Surgery, Tumor Ablation, and Observation.

Stephen R Grant, Xiudong Lei, Kenneth R Hess, Grace L Smith, Surena F Matin, Christopher G Wood, Quynh Nguyen, Steven J Frank, Mitchell S Anscher, Benjamin D Smith, Jose A Karam, Chad Tang,

<h4>Purpose</h4>Partial nephrectomy is the preferred definitive treatment for early stage kidney cancer, with tumor ablative techniques or active surveillance reserved for patients not undergoing surgery. Stereotactic body radiation therapy (SBRT) has emerged as a potential noninvasive alternative for patients with early stage kidney cancer not amenable to surgery, with early ... Read more >>

Adv Radiat Oncol (Advances in radiation oncology)
[2020, 5(3):495-502]

Cited: 0 times

View full text PDF listing >>



Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers.

Gabriel G Malouf, Ronan Flippot, Yiyu Dong, Renzo G Dinatale, Ying-Bei Chen, Xiaoping Su, Eva Compérat, Morgan Rouprêt, Roy Mano, Kyle A Blum, Hui Yao, Roger Mouawad, Jean-Philippe Spano, David Khayat, Jose A Karam, Thai H Ho, Satish K Tickoo, Paul Russo, James J Hsieh, Nizar M Tannir, Abraham A Hakimi,

Sarcomatoid clear-cell renal cell carcinomas (sRCC) are associated with dismal prognosis. Genomic alterations associated with sarcomatoid dedifferentiation are poorly characterized. We sought to define the genomic landscape of sRCC and uncover potentially actionable therapeutic targets. We assessed the genomic landscape of sRCC using targeted panel sequencing including patients with microdissected ... Read more >>

Sci Rep (Scientific reports)
[2020, 10(1):701]

Cited: 7 times

View full text PDF listing >>



PTRF independently predicts progression and survival in multiracial upper tract urothelial carcinoma following radical nephroureterectomy.

Hsin-Chih Yeh, Vitaly Margulis, Nirmish Singla, Elizabeth Hernandez, Vandana Panwar, Solomon L Woldu, Jose A Karam, Christopher G Wood, Alon Z Weizer, Jay D Raman, Mesut Remzi, Nathalie Rioux-Leclercq, Andrea Haitel, Marco Roscigno, Christian Bolenz, Karim Bensalah, Ching-Chia Li, Hung-Lung Ke, Wei-Ming Li, Hsiang-Ying Lee, Leonid M Rapoport, Yair Lotan, Payal Kapur, Shahrokh F Shariat, Jer-Tsong Hsieh, Wen-Jeng Wu,

<h4>Objectives</h4>Polymerase I and transcript release factor (PTRF) has been implicated in cancer biology but its role in upper tract urothelial carcinoma (UTUC) is unknown. From a pilot transcriptome, we identified PTRF was significantly upregulated in high stage UTUC. Bladder cancer transcriptome from The Cancer Genome Atlas (TCGA) supported our finding ... Read more >>

Urol Oncol (Urologic oncology)
[2020, 38(5):496-505]

Cited: 0 times

View full text PDF listing >>



Predicting Adherent Perinephric Fat Using Preoperative Clinical and Radiological Factors in Patients Undergoing Partial Nephrectomy.

Leonardo D Borregales, Mehrad Adibi, Arun Z Thomas, Rodolfo B Reis, Lisly J Chery, Catherine E Devine, Xuemei Wang, Aaron M Potretzke, Theodora Potretzke, Robert S Figenshau, Tyler M Bauman, Yara I Aboshady, Edwin Jason Abel, Surena F Matin, Jose A Karam, Christopher G Wood,

<h4>Background</h4>The decision to perform a partial nephrectomy (PN) relies largely upon the complexity of the renal mass and its surrounding anatomy. The presence of adherent perinephric fat (APF) can increase surgical complexity and extend operative times. The accurate prediction of APF may improve surgical planning and aid in decision making ... Read more >>

Eur Urol Focus (European urology focus)
[2021, 7(2):397-403]

Cited: 3 times

View full text PDF listing >>



Evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma of variant histology.

Omar Alhalabi, Jose A Karam, Nizar M Tannir,

<h4>Purpose of review</h4>Summarize current evidence for cytoreductive nephrectomy in patients with metastatic renal cell carcinoma (mRCC) of variant histology.<h4>Recent findings</h4>The mainstream treatment for advanced malignancy is systematic therapy, including chemotherapy, targeted therapy, and immunotherapy. Nonetheless, cytoreductive nephrectomy has been used in the management of mRCC including variant (nonclear cell) histology. ... Read more >>

Curr Opin Urol (Current opinion in urology)
[2019, 29(5):521-525]

Cited: 0 times

View full text PDF listing >>



Advertisement

Disclaimer
1.3474 s